Dr Mark Robson specialises in the identification and management of people who have inherited an increased risk for cancer. Around five to ten per cent of all cancers are directly linked to inherited gene defects. Dr Robson concentrates on helping men and women with cancer incorporate genetic information into their treatment plan.
Germline genetic testing was first used to identify people at risk of an inherited cancer, enabling clinicians to monitor and apply risk reduction approaches to patients.
This presentation will explore the eligibility for patient testing and will highlight which genes should be studied in order to understand the best treatment options. There will be an opportunity for questions.
Dr Mark Robson
Mark Robson is an Associate Attending Physician of the Clinical Genetics and Breast Cancer Medicine Services in the Department of Medicine at Memorial Sloan-Kettering Cancer Center.
Dr Robson's clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation–associated breast cancer. In addition to developing PARP inhibition as a therapeutic strategy, he is currently developing new models for the acquisition of germline information, including "mainstreaming" through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He is currently investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition.
Wednesday 10 March 2021